{ "instance": { "dna-20220331.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 310, "dts": { "calculationLink": { "local": [ "dna-20220331_cal.xml" ] }, "definitionLink": { "local": [ "dna-20220331_def.xml" ] }, "inline": { "local": [ "dna-20220331.htm" ] }, "labelLink": { "local": [ "dna-20220331_lab.xml" ] }, "presentationLink": { "local": [ "dna-20220331_pre.xml" ] }, "schema": { "local": [ "dna-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 671, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 38, "http://www.ginkgobioworks.com/20220331": 1, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 43 }, "keyCustom": 47, "keyStandard": 253, "memberCustom": 42, "memberStandard": 49, "nsprefix": "dna", "nsuri": "http://www.ginkgobioworks.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Investments and Equity Method Investments", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureInvestmentsAndEquityMethodInvestments", "shortName": "Investments and Equity Method Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Variable Interest Entities", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntities", "shortName": "Variable Interest Entities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Supplemental Balance Sheet Information", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformation", "shortName": "Supplemental Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Goodwill and Intangible Assets, net", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet", "shortName": "Goodwill and Intangible Assets, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Commitments and Contingencies", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Stock-Based Compensation", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Revenue Recognition", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Segment Information", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Significant Collaboration Transactions", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactions1", "shortName": "Significant Collaboration Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Net Loss per Share", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Related Parties", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Subsequent Events", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Variable Interest Entities (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesTables", "shortName": "Variable Interest Entities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Supplemental Balance Sheet Information (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables", "shortName": "Supplemental Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Investments and Equity Method Investments (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureInvestmentsAndEquityMethodInvestmentsTables", "shortName": "Investments and Equity Method Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Goodwill and Intangible Assets, net (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables", "shortName": "Goodwill and Intangible Assets, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Stock Based Compensation (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Segment Information (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Related Parties (Tables)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesTables", "shortName": "Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_1b4810e6-1fef-4bba-b092-38aa705513f3", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_526559bf-0fb6-4fbd-90b4-5df4fb37f35a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Fair Value Measurements - Summary of Change in the Fair Value of the Warrant Liabilities (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "shortName": "Fair Value Measurements - Summary of Change in the Fair Value of the Warrant Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_526559bf-0fb6-4fbd-90b4-5df4fb37f35a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_92c42086-725b-47d1-b3c4-878a93fb7e3d", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements Inputs (Detail)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail", "shortName": "Fair Value Measurements - Summary of Fair Value Measurements Inputs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_92c42086-725b-47d1-b3c4-878a93fb7e3d", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeconsolidationGainOrLossAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Variable Interest Entities (Additional Information) (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "shortName": "Variable Interest Entities (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_9d551bd9-54c6-4088-afc2-3f927271999d", "decimals": "-5", "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Variable Interest Entities - Summary of VIE assets and Liabilities (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails", "shortName": "Variable Interest Entities - Summary of VIE assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "div", "us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_6aaf2bab-b7ca-4994-93ab-120d1e481c46", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statement of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Supplemental Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Supplemental Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory, Net (Detail)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail", "shortName": "Supplemental Balance Sheet Information - Schedule of Inventory, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail", "shortName": "Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCapitalizationTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Supplemental Balance Sheet Information - Capitalization (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails", "shortName": "Supplemental Balance Sheet Information - Capitalization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCapitalizationTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCapitalizationTextBlock", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Supplemental Balance Sheet Information (Additional Information) (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "shortName": "Supplemental Balance Sheet Information (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_c3cc34c0-2658-412f-b94d-bd1ebd4a9be5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Goodwill (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillDetails", "shortName": "Goodwill and Intangible Assets, net - Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_b15b36be-cd35-482c-b496-8c4b4587deff", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_b15b36be-cd35-482c-b496-8c4b4587deff", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "p", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Parenthetical) (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsParentheticalDetails", "shortName": "Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "p", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Goodwill and Intangible Assets, net - Additional Information (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails", "shortName": "Goodwill and Intangible Assets, net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_2b4a7781-52b8-494e-adf9-a05f647563b8", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_2b4a7781-52b8-494e-adf9-a05f647563b8", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Stock-Based Compensation - Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "shortName": "Stock-Based Compensation - Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_04153019-88ce-4590-94b6-360cea5f7389", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_04153019-88ce-4590-94b6-360cea5f7389", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_c3cc34c0-2658-412f-b94d-bd1ebd4a9be5", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_c3cc34c0-2658-412f-b94d-bd1ebd4a9be5", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_91e981cd-a53c-4356-a2b0-9e068157e180", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "shortName": "Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_9d23fd79-69ff-491e-972b-48e8a66b8a4e", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_652d0820-5f27-4c6c-917d-98115bae5b18", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dna:SummaryOfEarnoutRsusTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_0793445b-5d25-4b33-8db9-136161b1af30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "INF", "first": true, "lang": null, "name": "dna:FoundryRevenuePercentage", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "INF", "first": true, "lang": null, "name": "dna:FoundryRevenuePercentage", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Revenue Recognition - Additional Information (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Revenue Recognition - Additional Information 1 (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformation1Details", "shortName": "Revenue Recognition - Additional Information 1 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_1df9e611-c8bc-4894-a378-451fe3e7622f", "decimals": null, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Segment Information Schedule of Segment Reporting Information, by Segment (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "shortName": "Segment Information Schedule of Segment Reporting Information, by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_77c8d2a8-09a2-4ca2-a6c3-28b496ea028b", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-5", "first": true, "lang": null, "name": "dna:EmployerPayrollTaxes", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Parenthetical) (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentParentheticalDetails", "shortName": "Segment Information - Schedule of Segment Reporting Information, by Segment (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-5", "first": true, "lang": null, "name": "dna:EmployerPayrollTaxes", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_741a3c27-69a3-4c77-958c-208dc71f89ef", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_741a3c27-69a3-4c77-958c-208dc71f89ef", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "INF", "first": true, "lang": null, "name": "dna:NumberOfAdditionalCommonUnitsReceived", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Significant Collaboration Transactions - Additional Information (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "shortName": "Significant Collaboration Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "INF", "first": true, "lang": null, "name": "dna:NumberOfAdditionalCommonUnitsReceived", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Net Loss per Share - Summary Of Anti-Dilutive Shares (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "shortName": "Net Loss per Share - Summary Of Anti-Dilutive Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Related Parties - Summary of Condensed Consolidated Balance Sheets (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "shortName": "Related Parties - Summary of Condensed Consolidated Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_5d8678c9-766b-4101-8e19-6ba11fc285d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Related Parties - Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "shortName": "Related Parties - Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_9d885dfe-d42f-41f3-a158-4be40b12efd2", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_68a20a0d-ea22-4ad2-a03e-ef23af935746", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredOther1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Subsequent Events (Additional Information) (Details)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_68a20a0d-ea22-4ad2-a03e-ef23af935746", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredOther1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Consolidated Statement of Cash Flows", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "shortName": "Condensed Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "lang": null, "name": "dna:ChangesInFairValueOfLoansReceivable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "dna:AccountsReceivableFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": "-3", "first": true, "lang": null, "name": "dna:AccountsReceivableFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dna-20220331.htm", "contextRef": "C_781f84ce-3492-4142-92d9-b395e1fbd45c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 105, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current", "terseLabel": "Entity Bankruptcy Proceedings Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dna_AccessBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Access Bio.", "label": "Access Bio [Member]", "terseLabel": "Access Bio [Member]" } } }, "localname": "AccessBioMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_AccountsReceivableFromRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable From Related Parties", "label": "Accounts Receivable From Related Parties", "terseLabel": "Accounts Receivable From Related Parties" } } }, "localname": "AccountsReceivableFromRelatedParties", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "dna_AdditionalAreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Area Of Real Estate Property", "label": "Additional Area Of Real Estate Property" } } }, "localname": "AdditionalAreaOfRealEstateProperty", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "dna_AdditionalCommonUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional common units.", "label": "Additional Common Units", "terseLabel": "Additional common units" } } }, "localname": "AdditionalCommonUnits", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dna_AdditionalNonCashConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional Non Cash Consideration", "label": "Additional Non Cash Consideration", "terseLabel": "Additional non-cash consideration" } } }, "localname": "AdditionalNonCashConsideration", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dna_AdditionalPreferredUnitsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional preferred units issued.", "label": "Additional Preferred Units Issued", "terseLabel": "Additional preferred units issued" } } }, "localname": "AdditionalPreferredUnitsIssued", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dna_AdditionsPursuantToTheBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additions pursuant to the business combination.", "label": "Additions Pursuant To The Business Combination", "terseLabel": "Additions pursuant to the business combination" } } }, "localname": "AdditionsPursuantToTheBusinessCombination", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dna_AdjustmentForAdoptionOfAccountingStandard": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for adoption of accounting standard", "label": "Adjustment for adoption of accounting standard", "terseLabel": "Adjustment for adoption of accounting standard" } } }, "localname": "AdjustmentForAdoptionOfAccountingStandard", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "dna_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital Warrant Issued Share", "label": "Adjustments To Additional Paid In Capital Warrant Issued Share", "terseLabel": "Issuance of warrants to purchase Series D convertible preferred stock, Share" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShare", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "dna_AgricultureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agriculture [Member]", "label": "Agriculture [Member]", "terseLabel": "Agriculture" } } }, "localname": "AgricultureMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_AllocatedUpfrontNonCashConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allocated upfront non cash consideration.", "label": "Allocated Upfront Non Cash Consideration", "terseLabel": "Allocated upfront non-cash consideration" } } }, "localname": "AllocatedUpfrontNonCashConsideration", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dna_AllonniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allonnia [Member].", "label": "Allonnia [Member]", "terseLabel": "Allonnia [Member]" } } }, "localname": "AllonniaMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dna_AnnualBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual Base Rent", "label": "Annual Base Rent" } } }, "localname": "AnnualBaseRent", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_ArcaeaLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arcaea LLC.", "label": "Arcaea LLC [Member]" } } }, "localname": "ArcaeaLlcMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dna_ArcaeaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arcaea [Member].", "label": "Arcaea [Member]", "terseLabel": "Arcaea [Member]" } } }, "localname": "ArcaeaMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dna_AyanaBioLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ayana Bio LLC.", "label": "Ayana Bio LLC Member", "terseLabel": "Ayana Bio LLC [Member]" } } }, "localname": "AyanaBioLlcMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dna_AyanaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ayana member.", "label": "Ayana [Member]", "terseLabel": "Ayana [Member]" } } }, "localname": "AyanaMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "dna_BerkeleyLightsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Berkeley Lights, Inc.", "label": "Berkeley Lights, Inc. [Member]", "terseLabel": "Berkeley Lights, Inc. [Member]" } } }, "localname": "BerkeleyLightsIncMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_BiosecurityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biosecurity [Member]", "label": "Biosecurity [Member]", "terseLabel": "Biosecurity" } } }, "localname": "BiosecurityMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "dna_BiosecurityRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biosecurity revenue.", "label": "Biosecurity Revenue [Abstract]", "terseLabel": "Biosecurity revenue:" } } }, "localname": "BiosecurityRevenueAbstract", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "dna_BusinessCombinationConsiderationAdditionalPreferredShareSoldShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination Consideration Additional Preferred Share Sold, Share", "label": "Business Combination Consideration Additional Preferred Share Sold, Share", "terseLabel": "Additional share", "verboseLabel": "Additional preferred units issued" } } }, "localname": "BusinessCombinationConsiderationAdditionalPreferredShareSoldShare", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dna_BusinessCombinationConsiderationPreferredShareSoldShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination Consideration Preferred Share Sold, Share", "label": "Business Combination Consideration Preferred Share Sold, Share", "terseLabel": "Share Sold" } } }, "localname": "BusinessCombinationConsiderationPreferredShareSoldShare", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dna_CarryingValueOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "carrying value outstanding", "label": "carrying value outstanding" } } }, "localname": "CarryingValueOutstanding", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dna_CashPaymentInPlanModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payment in plan modification.", "label": "Cash Payment in Plan Modification" } } }, "localname": "CashPaymentInPlanModification", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_ChangeInFairValueOfWarrantLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of warrant liabilities.", "label": "Change In Fair Value Of Warrant Liabilities", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "ChangeInFairValueOfWarrantLiabilities", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_ChangesInFairValueOfLoansReceivable": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Changes in fair value of loans receivable.", "label": "Changes in Fair Value of Loans Receivable" } } }, "localname": "ChangesInFairValueOfLoansReceivable", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for class A ordinary shares subject to possible redemption.", "label": "Class A Ordinary Shares Subject to Possible Redemption [Policy Text Block]", "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption" } } }, "localname": "ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dna_CodmMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CODM [Member]", "label": "CODM [Member]" } } }, "localname": "CodmMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "dna_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Equipment and Software [Member].", "label": "Computer Equipment and Software [Member]" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "dna_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration [Member]" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "dna_ContractLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract Liabilities", "label": "Contract Liabilities", "terseLabel": "Contract liabilities" } } }, "localname": "ContractLiabilities", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dna_ControlsOfBoardOfDirectors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Controls of board of directors.", "label": "Controls of Board of Directors", "terseLabel": "Controls of Board of Directors" } } }, "localname": "ControlsOfBoardOfDirectors", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dna_ConversionDiscountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion discount percentage.", "label": "Conversion Discount Percentage", "terseLabel": "Conversion discount" } } }, "localname": "ConversionDiscountPercentage", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dna_CostsAndOperatingExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Costs and operating expenses:", "label": "Costs and operating expenses:", "terseLabel": "Costs and operating expenses:" } } }, "localname": "CostsAndOperatingExpenses", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "dna_CronosGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cronos Group Inc. [Member]", "label": "Cronos Group Inc. [Member]", "terseLabel": "Cronos Group Inc. [Member]" } } }, "localname": "CronosGroupIncMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "dna_CustomerAndTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer And Technology [Member]", "label": "Customer And Technology [Member]", "terseLabel": "Customer And Technology" } } }, "localname": "CustomerAndTechnologyMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_DebtInstrumentUnpaidPrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument Unpaid Principal Amount", "label": "Debt Instrument Unpaid Principal Amount", "terseLabel": "Unpaid Principal Amount" } } }, "localname": "DebtInstrumentUnpaidPrincipalAmount", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_DeconsolidationOfSubsidiaryNote4": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deconsolidation of Subsidiary (Note 4)", "label": "Deconsolidation of Subsidiary (Note 4)", "terseLabel": "Deconsolidation of subsidiary (Note 4)" } } }, "localname": "DeconsolidationOfSubsidiaryNote4", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "dna_DeconsolidationOfVerbBioticsLlc": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deconsolidation of Verb Biotics, LLC", "label": "Deconsolidation of Verb Biotics, LLC", "terseLabel": "Deconsolidation of Verb Biotics, LLC" } } }, "localname": "DeconsolidationOfVerbBioticsLlc", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "dna_DeferredOfferingCostsInAccountsPayableAndAccruedExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs in accounts payable and accrued expense", "label": "Deferred offering costs in accounts payable and accrued expense", "terseLabel": "Deferred offering costs in accounts payable and accrued expense" } } }, "localname": "DeferredOfferingCostsInAccountsPayableAndAccruedExpense", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_DeferredRevenueFromRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue from related parties", "label": "Deferred revenue from related parties", "verboseLabel": "Deferred revenue from related parties" } } }, "localname": "DeferredRevenueFromRelatedParties", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "dna_DeferredUnderwritingCommissionPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commission per unit.", "label": "Deferred Underwriting Commission Per Unit", "terseLabel": "Deferred underwriting commission per unit" } } }, "localname": "DeferredUnderwritingCommissionPerUnit", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "dna_DeferredUnderwritingCommissionsNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commissions noncurrent.", "label": "Deferred Underwriting Commissions Noncurrent", "terseLabel": "Deferred underwriting commissions noncurrent" } } }, "localname": "DeferredUnderwritingCommissionsNoncurrent", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_EarnOutSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earn-Out Shares [Member]", "label": "Earn-Out Shares [Member]", "terseLabel": "New Ginkgo Earn-out shares [Member]" } } }, "localname": "EarnOutSharesMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_EarnoutMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnout [Member]", "label": "Earnout [Member]", "terseLabel": "Earnout Shares" } } }, "localname": "EarnoutMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "dna_EarnoutRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnout restricted stock awards.", "label": "Earnout Restricted Stock Awards [Member]", "terseLabel": "Earnout RSAs [Member]" } } }, "localname": "EarnoutRestrictedStockAwardsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_EarnoutRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnout restricted stock units.", "label": "Earnout Restricted Stock Units [Member]", "terseLabel": "Earnout RSU [Member]" } } }, "localname": "EarnoutRestrictedStockUnitsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "domainItemType" }, "dna_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for emerging growth company.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging growth company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dna_EmployerPayrollTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employer payroll taxes.", "label": "Employer Payroll Taxes", "terseLabel": "Employer payroll taxes" } } }, "localname": "EmployerPayrollTaxes", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "dna_EquityInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity interest.", "label": "Equity Interest", "terseLabel": "Equity interest" } } }, "localname": "EquityInterest", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dna_EquityMethodInvestment": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment", "label": "Equity Method Investment", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestment", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "dna_EquityReceivedInRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity received in related parties.", "label": "Equity Received in Related Parties", "terseLabel": "Equity received in related parties" } } }, "localname": "EquityReceivedInRelatedParties", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_EstimatedLeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated lease commencement date", "label": "Estimated Lease Commencement Date", "terseLabel": "Estimated lease commencement date" } } }, "localname": "EstimatedLeaseCommencementDate", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "dna_ExtendTermLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extend term lease", "label": "Extend term lease" } } }, "localname": "ExtendTermLease", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "dna_FairValueMeasurementIssuanceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Issuance [Axis]" } } }, "localname": "FairValueMeasurementIssuanceAxis", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "stringItemType" }, "dna_FairValueMeasurementIssuanceDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Issuance [Domain]" } } }, "localname": "FairValueMeasurementIssuanceDomain", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "dna_Fixednoncashconsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "fixed\u00a0non-cash\u00a0consideration", "label": "Fixednoncashconsideration", "terseLabel": "Fixed non-cash consideration" } } }, "localname": "Fixednoncashconsideration", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dna_FoodAndNutritionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Food And Nutrition [Member]", "label": "Food And Nutrition [Member]", "terseLabel": "Food And Nutrition" } } }, "localname": "FoodAndNutritionMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder Shares.", "label": "Founder Shares [Member]", "terseLabel": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_FoundryRevenue": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foundry revenue.", "label": "Foundry Revenue", "terseLabel": "Foundry revenue (related party revenue of $13,528 and $12,660 for the three months ended March 31 2022 and 2021, respectively)", "verboseLabel": "Foundry" } } }, "localname": "FoundryRevenue", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "dna_FoundryRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundry Revenue [Member]", "label": "Foundry Revenue [Member]", "terseLabel": "Foundry Revenue [Member]" } } }, "localname": "FoundryRevenueMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "dna_FoundryRevenuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundry Revenue Percentage", "label": "Foundry Revenue Percentage", "terseLabel": "Total Foundry revenue" } } }, "localname": "FoundryRevenuePercentage", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "percentItemType" }, "dna_GenomaticaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genomatica [Member].", "label": "Genomatica [Member]", "terseLabel": "Genomatica [Member]" } } }, "localname": "GenomaticaMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "dna_GinkgoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ginkgo [Member]", "terseLabel": "Ginkgo [Member]" } } }, "localname": "GinkgoMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dna_GlycosynPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glycosyn Promissory Note [Member]", "label": "Glycosyn Promissory Note [Member]", "terseLabel": "Glycosyn Promissory Note [Member]" } } }, "localname": "GlycosynPromissoryNoteMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_GovernmentAndDefenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government and Defense [Member]", "label": "Government and Defense [Member]", "terseLabel": "Government and Defense" } } }, "localname": "GovernmentAndDefenseMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_GreaterThanFiveYearsAndNotMoreThanSixYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April\u00a01, 2024 - March 31, 2025 [Member]", "label": "Greater Than Five Years And Not More Than Six Years [Member]", "terseLabel": "Year Four [Member]" } } }, "localname": "GreaterThanFiveYearsAndNotMoreThanSixYearsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_GreaterThanFourYearsAndNotMoreThanFiveYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April\u00a01, 2023 - March 31, 2024 [Member]", "label": "Greater Than Four Years And Not More Than Five Years [Member]", "terseLabel": "Year Three [Member]" } } }, "localname": "GreaterThanFourYearsAndNotMoreThanFiveYearsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_GreaterThanOneYearAndNotMoreThanThreeYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October\u00a01, 2020 - March 31, 2022 [Member]", "label": "Greater Than One Year And Not More Than Three Years [Member]", "terseLabel": "Year One [Member]" } } }, "localname": "GreaterThanOneYearAndNotMoreThanThreeYearsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_GreaterThanThreeYearsAndNotMoreThanFourYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April\u00a01, 2022 - March 31, 2023 [Member]", "label": "Greater Than Three Years And Not More Than Four Years [Member]", "terseLabel": "Year Two [Member]" } } }, "localname": "GreaterThanThreeYearsAndNotMoreThanFourYearsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_IncreaseDecreaseInOperatingLeaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease) In Operating Lease Rent", "label": "Increase Decrease) In Operating Lease Rent", "terseLabel": "Increase in minimum monthly lease rent" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRent", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_IncreaseInMinimumMonthlyRentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase In Minimum Monthly Rent Percentage", "label": "Increase In Minimum Monthly Rent Percentage" } } }, "localname": "IncreaseInMinimumMonthlyRentPercentage", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dna_IncreaseInMonthlyBaseRentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase In Monthly Base Rent Percentage", "label": "Increase In Monthly Base Rent Percentage" } } }, "localname": "IncreaseInMonthlyBaseRentPercentage", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dna_IndustrialAndEnvironmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Industrial And Environment [Member]", "label": "Industrial And Environment [Member]", "terseLabel": "Industrial And Environment" } } }, "localname": "IndustrialAndEnvironmentMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_InvestmentsHeldInTrustAccountPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investments held in trust account.", "label": "Investments Held In Trust Account [Policy Text Block]", "terseLabel": "Investment Held in Trust Account" } } }, "localname": "InvestmentsHeldInTrustAccountPolicyTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dna_IssuanceOfCommonStockOptionsAndVestingOfRestrictedStocksUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock options and vesting of restricted stocks units.", "label": "Issuance of Common Stock Options and Vesting of Restricted Stocks Units", "terseLabel": "Issuance of common stock upon exercise or vesting of equity awards, Shares" } } }, "localname": "IssuanceOfCommonStockOptionsAndVestingOfRestrictedStocksUnits", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "dna_IssuanceOfCommonStockOptionsValueAndVestingOfRestrictedStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of stock options and vesting of restricted stock units.", "label": "Issuance Of Common Stock Options Value And Vesting Of Restricted Stock Units", "terseLabel": "Issuance of common stock upon exercise or vesting of equity awards" } } }, "localname": "IssuanceOfCommonStockOptionsValueAndVestingOfRestrictedStockUnits", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "dna_IssuanceOfLoansReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of loans receivable.", "label": "Issuance Of Loans Receivable", "terseLabel": "Issuance of loans receivable" } } }, "localname": "IssuanceOfLoansReceivable", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dna_JoynMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joyn [Member].", "label": "Joyn [Member]", "terseLabel": "Joyn [Member]" } } }, "localname": "JoynMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "dna_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lab equipment.", "label": "Lab Equipment [Member]", "terseLabel": "Lab Equipment [Member]" } } }, "localname": "LabEquipmentMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "dna_LeaseFinancingObligationForBuildToSuitLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease financing obligation for build-to-suit lease", "label": "Lease financing obligation for build-to-suit lease" } } }, "localname": "LeaseFinancingObligationForBuildToSuitLease", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_LiquidityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity [Policy Text Block].", "label": "Liquidity [Policy Text Block]", "terseLabel": "Liquidity" } } }, "localname": "LiquidityPolicyTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dna_LoanReceivableReceivedAsConsiderationUnderCustomerArrangement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loan receivable received as consideration under customer arrangement", "label": "Loan receivable received as consideration under customer arrangement", "terseLabel": "Loans receivable issued for Foundry services" } } }, "localname": "LoanReceivableReceivedAsConsiderationUnderCustomerArrangement", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_MilestonePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Percentage", "label": "Milestone Percentage" } } }, "localname": "MilestonePercentage", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dna_MonthlyBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Monthly Base Rent", "label": "Monthly Base Rent" } } }, "localname": "MonthlyBaseRent", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_MotifMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Motif [Member]", "label": "Motif [Member]", "terseLabel": "Motif [Member]" } } }, "localname": "MotifMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "dna_NetLiabilitiesDerecognizedDueToDeconsolidationOfASubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net liabilities derecognized due to deconsolidation of a subsidiary.", "label": "Net Liabilities Derecognized Due to Deconsolidation of a Subsidiary", "negatedLabel": "Net liabilities derecognized due to deconsolidation of a subsidiary", "terseLabel": "Net liabilities derecognized due to deconsolidation of a subsidiary" } } }, "localname": "NetLiabilitiesDerecognizedDueToDeconsolidationOfASubsidiary", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_NonEmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Employee Stock [Member]", "label": "Non-Employee Stock [Member]", "terseLabel": "Non-Employee [Member]" } } }, "localname": "NonEmployeeStockMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_NumberOfAdditionalCommonUnitsReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional common units received", "label": "Number Of Additional Common Units Received", "terseLabel": "Number of additional common units received" } } }, "localname": "NumberOfAdditionalCommonUnitsReceived", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dna_NumberOfAllocatedPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of allocated performance obligations.", "label": "Number Of Allocated Performance Obligations", "terseLabel": "Number of allocated performance obligations" } } }, "localname": "NumberOfAllocatedPerformanceObligations", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dna_NumberOfCommonUnitsReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common units received", "label": "Number Of Common Units Received", "terseLabel": "Number of common units received" } } }, "localname": "NumberOfCommonUnitsReceived", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dna_OfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering cost.", "label": "Offering Cost", "terseLabel": "Offering cost" } } }, "localname": "OfferingCost", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_OfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for offering costs.", "label": "Offering Costs [Policy Text Block]", "terseLabel": "Offering costs" } } }, "localname": "OfferingCostsPolicyTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dna_OfferingCostsRelatedToWarrantLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs related to warrant liabilities.", "label": "Offering Costs Related To Warrant Liabilities", "negatedLabel": "Offering costs related to warrant liabilities", "terseLabel": "Offering costs related to warrant liabilities" } } }, "localname": "OfferingCostsRelatedToWarrantLiabilities", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_OfficeAndLaboratoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office And Laboratory [Member]", "label": "Office And Laboratory [Member]" } } }, "localname": "OfficeAndLaboratoryMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_OldGinkgoCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Old Ginkgo Common Stock [Member]", "label": "Old Ginkgo Common Stock [Member]", "terseLabel": "Old Ginkgo Common Stock [Member]" } } }, "localname": "OldGinkgoCommonStockMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "dna_OperatingExpensesNotAllocatedToSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating expenses not allocated to segments abstract", "label": "Operating expenses not allocated to segments abstract" } } }, "localname": "OperatingExpensesNotAllocatedToSegmentsAbstract", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "dna_OtherEquityInvestessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Equity Investess [Member]", "label": "Other Equity Investess [Member]" } } }, "localname": "OtherEquityInvestessMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "dna_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other [Member]", "label": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_PharmaAndBiotechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharma and Biotech [Member]", "label": "Pharma and Biotech [Member]", "terseLabel": "Pharma and Biotech" } } }, "localname": "PharmaAndBiotechMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Warrants.", "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants [Member]" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "dna_ProbabilitiesRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probabilities rate", "label": "Probabilities rate", "terseLabel": "Probabilities rate" } } }, "localname": "ProbabilitiesRate", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dna_ProceedsFromCapitalizedFinancing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from capitalized Financing", "label": "Proceeds from capitalized Financing", "terseLabel": "Proceeds from capitalized financing" } } }, "localname": "ProceedsFromCapitalizedFinancing", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dna_ProceedsFromLoansReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from loans receivable.", "label": "Proceeds From Loans Receivable", "negatedLabel": "Proceeds from loans receivable" } } }, "localname": "ProceedsFromLoansReceivable", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dna_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note.", "label": "Promissory Note [Member]", "terseLabel": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrants.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "dna_PurchaseOfNonCashMarketableEquitySecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Of Non Cash Marketable Equity Securities.", "label": "Purchase Of Non Cash Marketable Equity Securities", "terseLabel": "Warrants received for Foundry services" } } }, "localname": "PurchaseOfNonCashMarketableEquitySecurities", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_PurchaseOfNonMarketableEquitySecurities": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of non-marketable equity securities.", "label": "Purchase of Non-Marketable Equity Securities", "negatedLabel": "Prepayment for marketable equity securities", "terseLabel": "Purchase of non-marketable securities" } } }, "localname": "PurchaseOfNonMarketableEquitySecurities", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_PurchasesOfEquipmentThroughCapitalLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases of equipment through capital leases", "label": "Purchases of equipment through capital leases" } } }, "localname": "PurchasesOfEquipmentThroughCapitalLeases", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases of property and equipment included in accounts payable and accrued expenses", "label": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dna_RecognizedSharesOfDerivativeWarrantLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recognized shares of derivative warrant liabilities.", "label": "Recognized Shares Of Derivative Warrant Liabilities", "terseLabel": "Recognized shares of derivative warrant liabilities" } } }, "localname": "RecognizedSharesOfDerivativeWarrantLiabilities", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dna_RecoveryRateOnFirstLienDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recovery rate on first lien debt", "label": "Recovery rate on first lien debt", "terseLabel": "Recovery rate on first lien debt" } } }, "localname": "RecoveryRateOnFirstLienDebt", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dna_RemainingRestrictedSharesSubjectToRegulatorySalesRestrictions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining restricted shares subject to regulatory sales restrictions", "label": "Remaining restricted shares subject to regulatory sales restrictions" } } }, "localname": "RemainingRestrictedSharesSubjectToRegulatorySalesRestrictions", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dna_RestOfTheWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of The World [Member]", "label": "Rest of The World [Member]" } } }, "localname": "RestOfTheWorldMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dna_RestrictedInvestmentsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted investments term.", "label": "Restricted Investments Term", "terseLabel": "Restricted investments term" } } }, "localname": "RestrictedInvestmentsTerm", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "dna_RestrictedStockAwardsAndEarnoutRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock awards and earnout restricted stock awards.", "label": "Restricted Stock Awards and Earnout Restricted Stock Awards [Member]" } } }, "localname": "RestrictedStockAwardsAndEarnoutRestrictedStockAwardsMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_RevenueFromContractWithCustomerPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer Percentage", "label": "Revenue From Contract With Customer Percentage", "terseLabel": "Total revenue", "totalLabel": "Foundry Revenue" } } }, "localname": "RevenueFromContractWithCustomerPercentage", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "percentItemType" }, "dna_SalesRestrictedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales restricted shares", "label": "Sales Restricted Shares", "terseLabel": "Sales Restricted Shares" } } }, "localname": "SalesRestrictedShares", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dna_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Changes In The Fair Value Of Warrant Liabilities.", "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities [Abstract]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAbstract", "nsuri": "http://www.ginkgobioworks.com/20220331", "xbrltype": "stringItemType" }, "dna_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Changes In The Fair Value Of Warrant Liabilities.", "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesLineItems", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "dna_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Changes In The Fair Value Of Warrant Liabilities.", "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities [Table]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTable", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "dna_SegmentOperatingIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Segment Operating Income (Loss)", "label": "Segment Operating Income (Loss)", "terseLabel": "Total segment operating income (loss)" } } }, "localname": "SegmentOperatingIncomeLoss", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "dna_SeriesBCDEConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B, C, D, E Convertible Preferred Stock [Member]", "label": "Series B, C, D, E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBCDEConvertiblePreferredStockMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "dna_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "dna_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Preferred Stock [Member]", "label": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "dna_SeriesEConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Convertible Preferred Stock [Member]", "label": "Series E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesEConvertiblePreferredStockMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate", "terseLabel": "Discount Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountRate", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskAdjsutedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value assumptions risk adjsuted Interest rate", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Adjsuted Interest Rate", "terseLabel": "Risk adjusted rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskAdjsutedInterestRate", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "dna_ShareBasedCompensationAwardTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award tranche four member.", "label": "Share Based Compensation Award Tranche Four Member", "terseLabel": "20.00 Then 25% [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheFourMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_ShareIssuedInExchangeForTheRightsToCertainIntellectualProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share issued in exchange for the rights to certain intellectual property.", "label": "Share issued In Exchange For The Rights To Certain Intellectual Property" } } }, "localname": "ShareIssuedInExchangeForTheRightsToCertainIntellectualProperty", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dna_SharesValuedBasedOnUnadjustedPriceDiscountRemoved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares valued based on unadjusted price, Discount removed", "label": "Shares valued based on unadjusted price, Discount removed" } } }, "localname": "SharesValuedBasedOnUnadjustedPriceDiscountRemoved", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dna_SignificantAccountingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policy", "label": "Significant Accounting Policy Text Block", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPolicyTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dna_SignificantCollaborationTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Collaboration Transactions [Abstract]", "label": "Significant Collaboration Transactions [Abstract]" } } }, "localname": "SignificantCollaborationTransactionsAbstract", "nsuri": "http://www.ginkgobioworks.com/20220331", "xbrltype": "stringItemType" }, "dna_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sponsor.", "label": "Sponsor [Member]", "terseLabel": "Sponsor [Member]" } } }, "localname": "SponsorMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_SummaryOfEarnoutRsusTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Earnout RSUs Table Text Block.", "label": "Summary Of Earnout RSUs Table Text Block", "terseLabel": "Summary of Activity For Earnout RSA" } } }, "localname": "SummaryOfEarnoutRsusTableTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "dna_SupplementalFinancialStatementInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Financial Statement Information [Abstract]", "label": "Supplemental Financial Statement Information [Abstract]" } } }, "localname": "SupplementalFinancialStatementInformationAbstract", "nsuri": "http://www.ginkgobioworks.com/20220331", "xbrltype": "stringItemType" }, "dna_SynlogicIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Synlogic, Inc. [Member]", "label": "Synlogic, Inc. [Member]", "terseLabel": "Synlogic, Inc. [Member]" } } }, "localname": "SynlogicIncMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "dna_SynlogicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Synlogic [Member]", "label": "Synlogic [Member]", "terseLabel": "Synlogic [Member]" } } }, "localname": "SynlogicMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "dna_TotalConsiderationReceivedInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total consideration received in shares.", "label": "Total Consideration Received In Shares", "terseLabel": "Total consideration" } } }, "localname": "TotalConsiderationReceivedInShares", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dna_TwistBioscienceCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twist Bioscience Corporation.", "label": "Twist Bioscience Corporation [Member]" } } }, "localname": "TwistBioscienceCorporationMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one employee stock purchase plan.", "label": "Two Thousand and Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one incentive award plan.", "label": "Two Thousand and Twenty One Incentive Award Plan [Member]", "terseLabel": "2021 Incentive Award Plan [Member]" } } }, "localname": "TwoThousandAndTwentyOneIncentiveAwardPlanMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_TwoThousandsAndEightStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousands And Eight Stock Incentive Plan [Member].", "label": "Two Thousands And Eight Stock Incentive Plan [Member]", "terseLabel": "2008 Stock Incentive Plan" } } }, "localname": "TwoThousandsAndEightStockIncentivePlanMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_TwoThousandsAndFourteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousands And Fourteen Stock Incentive Plan [Member]", "label": "Two Thousands And Fourteen Stock Incentive Plan [Member]", "terseLabel": "2014 Stock Incentive Plan" } } }, "localname": "TwoThousandsAndFourteenStockIncentivePlanMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_UnderwritingDiscountPaidPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting discount paid per unit.", "label": "Underwriting Discount Paid Per Unit", "terseLabel": "Underwriting discount paid per unit" } } }, "localname": "UnderwritingDiscountPaidPerUnit", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "dna_UndiscountedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undiscounted shares.", "label": "Undiscounted Shares", "terseLabel": "Undiscounted Shares" } } }, "localname": "UndiscountedShares", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "dna_UsGovernmentSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US Government Securities.", "label": "US Government Securities [Member]", "terseLabel": "US Government Securities" } } }, "localname": "UsGovernmentSecuritiesMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dna_VerbBioticsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Verb Biotics LLC.", "label": "Verb Biotics LLC Member", "terseLabel": "Verb Biotics LLC [Member]" } } }, "localname": "VerbBioticsLlcMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dna_VerbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Verb member.", "label": "Verb [Member]", "terseLabel": "Verb [Member]" } } }, "localname": "VerbMember", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "dna_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrant liability.", "label": "Warrant Liability [Policy Text Block]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dna_WeightedAverageTimingBasedOnDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Timing Based On Discount rate", "label": "Weighted Average Timing Based On Discount rate" } } }, "localname": "WeightedAverageTimingBasedOnDiscountRate", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "dna_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working Capital Deficit", "terseLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dna_YearsToMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Years to maturity", "label": "Years to Maturity", "terseLabel": "Years to Maturity" } } }, "localname": "YearsToMaturity", "nsuri": "http://www.ginkgobioworks.com/20220331", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.", "label": "Condensed Statement of Comprehensive Income [Table Text Block]", "terseLabel": "Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss" } } }, "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r124", "r252", "r257", "r263", "r422", "r423", "r432", "r433", "r503", "r618", "r632", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r124", "r252", "r257", "r263", "r422", "r423", "r432", "r433", "r503", "r618", "r632", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r269", "r291", "r335", "r338", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r582", "r585", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r269", "r291", "r335", "r338", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r582", "r585", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of North America.", "label": "North America [Member]" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r194", "r312", "r316", "r525", "r581", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r194", "r312", "r316", "r525", "r581", "r583" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r269", "r291", "r324", "r335", "r338", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r582", "r585", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r269", "r291", "r324", "r335", "r338", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r582", "r585", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r134", "r136", "r137", "r139", "r140", "r151", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r151", "r212", "r213", "r377", "r394", "r450", "r451", "r452", "r453", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r151", "r212", "r213", "r377", "r394", "r450", "r451", "r452", "r453", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r135", "r336", "r630" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Forecast 2023 [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r126", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r137", "r139", "r140", "r151", "r212", "r213", "r377", "r394", "r450", "r451", "r452", "r453", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r135", "r141", "r336" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r195", "r196", "r312", "r317", "r584", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r631", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r195", "r196", "r312", "r317", "r584", "r604", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r631", "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r135", "r141", "r244", "r336", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r46", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r27", "r200", "r201" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r26", "r122", "r498", "r500", "r571" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r57", "r122", "r498", "r500" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Accounts receivable - related parties" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued Liabilities and Other Liabilities, Total" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r44", "r238" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r69", "r70", "r71", "r567", "r591", "r595" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r68", "r71", "r78", "r79", "r80", "r126", "r127", "r128", "r430", "r586", "r587", "r648" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Intangible assets, weighted average amortization period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r377", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional\u00a0paid-in\u00a0capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r126", "r127", "r128", "r374", "r375", "r376", "r451" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r339", "r341", "r379", "r380" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r265", "r294", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of warrants to purchase Series D convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r341", "r369", "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r107", "r226", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "totalLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from the computation of diluted loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "auth_ref": [ "r410", "r411", "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Contingent consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r120", "r177", "r183", "r190", "r208", "r252", "r253", "r254", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r422", "r432", "r472", "r504", "r506", "r543", "r563" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r65", "r120", "r208", "r252", "r253", "r254", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r422", "r432", "r472", "r504", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets Held-in-trust", "terseLabel": "Cash held in trust Account", "totalLabel": "Assets Held-in-trust, Total" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r342", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r334", "r337" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r334", "r337", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Business Combination, total purchase price", "verboseLabel": "Business combination equity interests issued or issuable value" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Business Combination, Issue" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]", "terseLabel": "Business Combination [Line Items]" } } }, "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "verboseLabel": "Business combination share price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r402", "r403", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration", "totalLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Business Combination, Consideration Transferred, Other" } } }, "localname": "BusinessCombinationConsiderationTransferredOther1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r409" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High", "negatedLabel": "Change in fair value of contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r401", "r404", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration, included in other non-current liabilities", "totalLabel": "Business Combination, Contingent Consideration, Liability, Total" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitsMember": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.", "label": "Capital Units [Member]", "terseLabel": "Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant [Member]" } } }, "localname": "CapitalUnitsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r41", "r506", "r599", "r600" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash, Ending Balance", "periodStartLabel": "Cash, Beginning Balance", "terseLabel": "Cash and cash equivalents" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r41", "r109" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total included in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r12", "r110" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r12", "r110", "r541" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r103", "r109", "r112" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r103", "r473" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash Equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Cash, FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of\u00a0non-cash\u00a0financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r118", "r120", "r142", "r143", "r144", "r146", "r147", "r155", "r156", "r157", "r208", "r252", "r257", "r258", "r259", "r263", "r264", "r289", "r290", "r292", "r293", "r472", "r628" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r298", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Assumed Class Of Warrant Or Right Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Significant Collaboration Transactions" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactions1" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r243", "r551", "r574" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Class A common stock [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation.", "label": "Common Class C [Member]", "terseLabel": "Common Class C [Member]", "verboseLabel": "Non-Voting Class C common stock [Member]" } } }, "localname": "CommonClassCMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for issuance", "totalLabel": "Total common stock reserved for future issuances", "verboseLabel": "Total common stock reserved for future issuances" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r126", "r127", "r451" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par or stated value per share", "verboseLabel": "Common stock per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized", "verboseLabel": "Shares issued" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued", "totalLabel": "Common Stock, Shares, Issued, Total", "verboseLabel": "Shares held" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value (Note 5)", "totalLabel": "Common Stock, Value, Issued, Total", "verboseLabel": "Proceeds from capital contributions" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Common Unit, Issuance Value", "terseLabel": "Total consideration of common unit" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssued": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of common units issued of limited liability company (LLC).", "label": "Common Unit, Issued", "terseLabel": "Common units", "verboseLabel": "Common unit, received" } } }, "localname": "CommonUnitIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r73", "r75", "r76", "r85", "r555", "r578" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive loss", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:", "verboseLabel": "Proceeds from capital contributions" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment and Software [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r164", "r165", "r198", "r470", "r471", "r596", "r608" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r160", "r560" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r164", "r165", "r198", "r470", "r471" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Revenue percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r164", "r165", "r198", "r470", "r471", "r608" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r113", "r424" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r299", "r300", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract asset", "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual Obligation", "totalLabel": "Contractual Obligation, Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Four", "terseLabel": "Contractual Obligation, to be Paid, Year Four" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year One", "terseLabel": "Contractual Obligation, to be Paid, Year One" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Two", "terseLabel": "Contractual Obligation, to be Paid, Year Two" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Three", "terseLabel": "Contractual Obligation, to be Paid, Year Three" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r89", "r525" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Biosecurity revenue", "totalLabel": "Cost of Goods and Services Sold, Total" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r90", "r120", "r208", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Revenue", "totalLabel": "Cost of Revenue, Total", "verboseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Segment cost of revenue:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r163", "r198" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r119", "r124", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r483", "r544", "r545", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r275", "r284", "r285", "r467" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair Value Of Promissory Note", "totalLabel": "Debt Instrument, Fair Value Disclosure, Total" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r50", "r283", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Discount Rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r51", "r119", "r124", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r483" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Promissory Note Maturity" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_DeconsolidationGainOrLossAmount": { "auth_ref": [ "r431" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Deconsolidation, Gain (Loss), Amount", "negatedLabel": "Gain on deconsolidation of subsidiary (Note 4)", "terseLabel": "Gain on deconsolidation of subsidiary" } } }, "localname": "DeconsolidationGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r64", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Offering costs", "verboseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredPurchasedPowerCosts": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of power used for operations in prior periods that were expected to be recovered from customers in future periods.", "label": "Deferred Purchased Power Costs", "negatedLabel": "Payment of deferred offering costs" } } }, "localname": "DeferredPurchasedPowerCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r22", "r486", "r492" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.", "label": "Deferred Rent Credit, Noncurrent", "terseLabel": "Deferred rent, net of current portion" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenue", "totalLabel": "Deferred Revenue, Total" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue (includes $8,203 and $12,502 from related parties)", "totalLabel": "Deferred Revenue, Current, Total" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion (includes $143,037 and $148,319 from related parties)", "totalLabel": "Deferred Revenue, Noncurrent, Total" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Deferred revenue, Revenue recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r107", "r236" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r123", "r443", "r444", "r445", "r446", "r449" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Warrant Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired Developed Technology [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r312", "r316", "r317", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation Of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r7", "r13", "r26", "r122", "r255", "r257", "r258", "r262", "r263", "r264", "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from related parties", "totalLabel": "Due from Related Parties, Current, Total" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r46", "r122", "r255", "r257", "r258", "r262", "r263", "r264", "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Deferred revenue from related parties", "totalLabel": "Due to Related Parties, Current, Total" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r52", "r122", "r255", "r257", "r258", "r262", "r263", "r264", "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Deferred revenue, net of current portion from related parties", "totalLabel": "Due to Related Parties, Noncurrent, Total" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Ordinary Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r148", "r149", "r150", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r473" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "negatedLabel": "Effect of foreign exchange rates on cash and cash equivalents", "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents", "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r78", "r79", "r80", "r126", "r127", "r128", "r130", "r137", "r140", "r154", "r211", "r294", "r295", "r374", "r375", "r376", "r393", "r394", "r451", "r474", "r475", "r476", "r477", "r478", "r479", "r586", "r587", "r588", "r648" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Carrying value of equity method investment", "totalLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity, Total" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r3", "r120", "r208", "r472" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "terseLabel": "Other equity investees [Member]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentSoldCarryingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the entity's equity method investment which has been sold.", "label": "Equity Method Investment, Amount Sold", "terseLabel": "Carrying value of the equity method investment" } } }, "localname": "EquityMethodInvestmentSoldCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r42", "r178", "r205" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments", "verboseLabel": "Carrying value of the equity method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Investments and Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureInvestmentsAndEquityMethodInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r42", "r102", "r206", "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of Investments and Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureInvestmentsAndEquityMethodInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r107", "r288" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r454", "r455", "r456", "r463" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Fair Value Measurements Inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r454", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r454", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r275", "r284", "r285", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r455", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r454", "r455", "r458", "r459", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r275", "r325", "r326", "r331", "r333", "r455", "r511" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets (Level 1) [Member]", "verboseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r275", "r284", "r285", "r325", "r326", "r331", "r333", "r455", "r512" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r275", "r284", "r285", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r455", "r513" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 3) [Member]", "verboseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]" } } }, "localname": "FairValueInputsQuantitativeInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r460", "r463" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Change in the Fair Value of the Warrant Liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value", "verboseLabel": "Change in fair value of contingent consideration liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r275", "r284", "r285", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r462", "r464" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r488" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Lease financing obligation" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r489", "r491" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Principal payments on capital leases and lease financing obligation", "terseLabel": "Principal payment on lease financing obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "periodEndLabel": "Ending balance warrant liabilities", "periodStartLabel": "Beginning balance warrant liabilities", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r232" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Intangible assets, accumulated amortization", "terseLabel": "Intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months", "terseLabel": "Future amortization expense per year thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Future amortization expense for the remainder of 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r227", "r229", "r232", "r234", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r232", "r527" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets, gross carrying value", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r227", "r231" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r232", "r526" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "totalLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r93", "r107", "r204" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Gain on investments", "totalLabel": "Gain (Loss) on Investments, Total", "verboseLabel": "Gain on investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Abstract]", "terseLabel": "Segment general and administrative expense:" } } }, "localname": "GeneralAndAdministrativeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r219", "r220", "r506", "r542" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balances as of March 31, 2022", "periodStartLabel": "Balances as of December 31, 2021", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired in Dutch DNA acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets, net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedLabel": "Impact of foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r88", "r108", "r131", "r132", "r134", "r135", "r145", "r147", "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent, Total", "verboseLabel": "Loss from operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r82", "r177", "r182", "r186", "r189", "r192", "r540", "r553", "r557", "r579" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic and diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r83", "r107", "r175", "r205", "r552", "r576" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Loss on equity method investments", "terseLabel": "Loss on equity method investments", "totalLabel": "Income (Loss) from Equity Method Investments, Total", "verboseLabel": "Loss on equity method investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r139", "r140", "r176", "r386", "r395", "r396", "r580" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefit", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r77", "r384", "r385", "r389", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r111" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedLabel": "Taxes paid related to net share settlement of equity awards", "terseLabel": "Taxes paid related to net share settlement of equity awards", "totalLabel": "Income Taxes Paid, Net, Total" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "negatedLabel": "Accounts payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Accounts receivable, net from related parties" } } }, "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r106", "r522" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "negatedLabel": "Deferred revenue, current and non-current (includes $44,632 and $(17,050) from related parties)", "terseLabel": "Deferred revenue, current and non-current (($9,702) and ($6,491) from related parties)" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory, net", "totalLabel": "Increase (Decrease) in Inventories, Total" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Increase(Decrease) in intangible assets due to foreign currency translation" } } }, "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r225", "r230" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r556" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTotalLabel": "Total other income (expense), net", "terseLabel": "Interest expense, net", "totalLabel": "Interest Income (Expense), Net, Total" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r59" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "totalLabel": "Inventory, Finished Goods, Gross, Total" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r62", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r11", "r63", "r114", "r153", "r214", "r215", "r217", "r523" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, net" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r61" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "totalLabel": "Inventory, Raw Materials, Gross, Total" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r62", "r216" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Less: Inventory reserve", "periodEndLabel": "Inventory Valuation Reserves, Ending Balance", "periodStartLabel": "Inventory Valuation Reserves, Beginning Balance" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r60" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount": { "auth_ref": [ "r598" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of financial support to be provided in future by investment company to investee.", "label": "Investment Company, Financial Commitment to Investee, Future Amount", "terseLabel": "Company to Provide Further Financial Support" } } }, "localname": "InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r92", "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income earned on the trust account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r575" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments", "totalLabel": "Investments, Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Total included in investment", "totalLabel": "Investments, Fair Value Disclosure, Total" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeaseDescription": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Description of lessor's operating lease.", "label": "Lessor, Operating Lease, Description" } } }, "localname": "LessorOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeaseOptionToExtend": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessor's operating lease.", "label": "Lessor, Operating Lease, Option to Extend" } } }, "localname": "LessorOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48", "r120", "r184", "r208", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r423", "r432", "r433", "r472", "r504", "r505" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r120", "r208", "r472", "r506", "r548", "r570" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r120", "r208", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r423", "r432", "r433", "r472", "r504", "r505", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "label": "Liabilities, Fair Value Adjustment", "terseLabel": "Change in fair value of contingent consideration liability" } } }, "localname": "LiabilitiesFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r20", "r545", "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Letter of credit", "totalLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Increase in line of credit", "totalLabel": "Line of Credit Facility, Increase (Decrease), Net, Total" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Long Term Purchase Commitment Amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ManufacturingFacilityMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Structure used in the manufacturing of goods.", "label": "Manufacturing Facility [Member]", "terseLabel": "Facilities [Member]" } } }, "localname": "ManufacturingFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MemberUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership interest in limited liability company (LLC).", "label": "Member Units [Member]", "terseLabel": "Joyn" } } }, "localname": "MemberUnitsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r58", "r120", "r208", "r252", "r257", "r258", "r259", "r263", "r264", "r472", "r547", "r569" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "terseLabel": "Non-controlling interest", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "verboseLabel": "Minority Interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r103" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r103" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r103", "r105", "r108" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r72", "r74", "r80", "r84", "r108", "r120", "r129", "r131", "r132", "r134", "r135", "r139", "r140", "r145", "r177", "r182", "r186", "r189", "r192", "r208", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r453", "r472", "r554", "r577" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders", "verboseLabel": "Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r72", "r74", "r80", "r139", "r140", "r426", "r440" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to non-controlling interest", "terseLabel": "Net loss attributable to non-controlling interest", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetRentableArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net rentable area for properties owned.", "label": "Net Rentable Area", "terseLabel": "Rentable area" } } }, "localname": "NetRentableArea", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r296", "r421", "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Issuance of stock by subsidiary" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r126", "r127", "r128", "r295", "r416" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Minority Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r177", "r182", "r186", "r189", "r192" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total segment operating income (loss)", "totalLabel": "Loss from operations", "verboseLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseMinimumRentals": { "auth_ref": [ "r484", "r485", "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.", "label": "Operating Leases, Rent Expense, Minimum Rentals", "terseLabel": "Minimum Monthly Rent" } } }, "localname": "OperatingLeasesRentExpenseMinimumRentals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r419", "r420", "r429" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss2": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total", "verboseLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r67" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss2": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments, net of taxes", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "verboseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r108" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash activity", "terseLabel": "Other non-cash activity", "totalLabel": "Other Noncash Income (Expense), Total" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other income (expense), net:", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Cooksonia" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "terseLabel": "Payments for underwriting expense" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r96" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Prepayment for business acquisition", "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r96" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "negatedLabel": "Deconsolidation of subsidiary - cash", "totalLabel": "Payments to Acquire Interest in Subsidiaries and Affiliates, Total" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r342", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24", "r289" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24", "r289" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredUnitsIssued": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of preferred units issued.", "label": "Preferred Units, Issued", "terseLabel": "Preferred units" } } }, "localname": "PreferredUnitsIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r39", "r40" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Warrants Issued" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from related party debt", "verboseLabel": "Advances from Sponsor" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherInvestments": { "auth_ref": [ "r95" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale of investments classified as other.", "label": "Proceeds from Sale of Other Investments", "terseLabel": "Other" } } }, "localname": "ProceedsFromSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r98", "r373" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r72", "r74", "r80", "r101", "r120", "r129", "r139", "r140", "r177", "r182", "r186", "r189", "r192", "r208", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r419", "r425", "r427", "r440", "r441", "r453", "r472", "r557" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss2": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r44", "r239" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r43", "r237" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r239", "r506", "r559", "r573" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r237" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r21", "r546", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r21", "r546", "r565" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r21", "r546", "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Minimum purchase commitment in contract years" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesFairValueDisclosure": { "auth_ref": [ "r34", "r66", "r550", "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.", "label": "Receivables, Fair Value Disclosure", "terseLabel": "Receivables, Fair Value Disclosure", "totalLabel": "Receivables, Fair Value Disclosure, Total" } } }, "localname": "ReceivablesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r332", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r332", "r497", "r498", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r332", "r497", "r500", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r495", "r496", "r498", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "verboseLabel": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r382", "r524", "r621" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Abstract]", "terseLabel": "Segment research and development expense:" } } }, "localname": "ResearchAndDevelopmentExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r112", "r541", "r566" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "periodEndLabel": "Restricted cash, end of period", "periodStartLabel": "Restricted cash, beginning of period", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r4", "r12", "r112" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash included in prepaid expenses and other current assets" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "auth_ref": [ "r10", "r16", "r112", "r605", "r606", "r607" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash included in other non-current assets" } } }, "localname": "RestrictedCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "RSA [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Tax withholdings related to net share settlement of equity awards, Shares" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSU Activity [Member]", "verboseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Tax withholdings related to net share settlement of equity awards" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r295", "r377", "r506", "r568", "r590", "r595" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r126", "r127", "r128", "r130", "r137", "r140", "r211", "r374", "r375", "r376", "r393", "r394", "r451", "r586", "r588" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r172", "r173", "r181", "r187", "r188", "r194", "r195", "r198", "r311", "r312", "r525" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total Revenue", "totalLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r310", "r315", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r87", "r255", "r257", "r258", "r262", "r263", "r264", "r602" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Foundry revenue" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuePerformanceObligationSatisfiedOverTimeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue, Performance Obligation Satisfied over Time [Abstract]" } } }, "localname": "RevenuePerformanceObligationSatisfiedOverTimeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue Remaining Performance Obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformation1Details", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformation1Details" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformation1Details" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformation1Details" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Year in which remaining performance obligation is expected to be recognized, in YYYY format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Year", "terseLabel": "Revenue remaining performance obligation expected timing of satisfaction year" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformation1Details" ], "xbrltype": "gYearListItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r81", "r120", "r172", "r173", "r181", "r187", "r188", "r194", "r195", "r198", "r208", "r252", "r253", "r254", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r472", "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Revenues, Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary Of Anti-Dilutive Shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Schedule of the equity interest (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire an entity in a business combination.", "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the capitalization of the entity comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.", "label": "Schedule of Capitalization [Table Text Block]", "terseLabel": "Schedule of Capitalization" } } }, "localname": "ScheduleOfCapitalizationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r341", "r368", "r378" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r341", "r368", "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets and Liabilities That Are Measured At Fair Value On Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r227", "r231", "r526" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r36", "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Net" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r44", "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedBalanceSheetsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesSummaryOfCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Summary of Condensed Consolidated Balance Sheets" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r12", "r112", "r541", "r566" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r177", "r179", "r185", "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r342", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of RSU Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r347", "r358", "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r422", "r423", "r432", "r433", "r434", "r435", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r434", "r435", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Summary of VIE assets and Liabilities" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r169", "r170", "r171", "r177", "r180", "r186", "r190", "r191", "r192", "r193", "r194", "r197", "r198", "r199" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]", "terseLabel": "Segment operating income (loss):" } } }, "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "SegmentReportingInformationRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Segment general and administrative expense", "totalLabel": "Selling, General and Administrative Expense, Total" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Share-based compensation arrangement by share-based payment award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Share Forfeited", "terseLabel": "Number of Share Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of share, Granted", "verboseLabel": "No of awards granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "terseLabel": "Awards remeasured price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of shares, Nonvested at end of period (in shares)", "periodStartLabel": "Number of shares, Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value, Nonvested at end of period", "periodStartLabel": "Weighted average grant date fair value, Nonvested at beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of share, Vested", "terseLabel": "Number of share, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price per share, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Number of shares, Outstanding", "terseLabel": "Number of shares, Forfeited", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price per share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options, grants in period, weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r349", "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares, Ending balance", "periodStartLabel": "Number of shares , Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price per share, Ending balance", "periodStartLabel": "Weighted average exercise price per share, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r340", "r344" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price per share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price per share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "12.50 Then 25% [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]", "terseLabel": "17.50 Then 25% [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "15.00 Then 25% [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r342", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, Outstanding", "verboseLabel": "Weighted average remaining life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of restricted stock awards vested", "verboseLabel": "Fair value of vested stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r17", "r506", "r544", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "totalLabel": "Short-term Debt, Total" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r118", "r120", "r142", "r143", "r144", "r146", "r147", "r155", "r156", "r157", "r208", "r252", "r257", "r258", "r259", "r263", "r264", "r289", "r290", "r292", "r293", "r294", "r472", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSignificantCollaborationTransactionsAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r56", "r78", "r79", "r80", "r126", "r127", "r128", "r130", "r137", "r140", "r154", "r211", "r294", "r295", "r374", "r375", "r376", "r393", "r394", "r451", "r474", "r475", "r476", "r477", "r478", "r479", "r586", "r587", "r588", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r126", "r127", "r128", "r154", "r525" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationCapitalizationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period shares", "verboseLabel": "Issuance of common stock upon exercise of Public Warrants, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r294", "r295", "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of shares, Exercised", "terseLabel": "Exercise of stock options, Share", "verboseLabel": "Number of shares, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r31", "r32", "r120", "r202", "r208", "r472", "r506" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Ginkgo Bioworks Holdings, Inc. stockholders equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r79", "r120", "r126", "r127", "r128", "r130", "r137", "r208", "r211", "r295", "r374", "r375", "r376", "r393", "r394", "r416", "r417", "r439", "r451", "r472", "r474", "r475", "r479", "r587", "r588", "r648" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StraightLineRent": { "auth_ref": [ "r106" ], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.", "label": "Straight Line Rent", "terseLabel": "Deferred rent, non-current" } } }, "localname": "StraightLineRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r480", "r508" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r480", "r508" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r480", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r480", "r508" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r507", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInTheFairValueOfTheWarrantLiabilitiesDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TradingSecuritiesRestricted": { "auth_ref": [ "r117", "r203", "r520", "r549", "r562", "r597", "r603" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of all securities that are purchased with the intent to be sold in the short-term and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.", "label": "Trading Securities, Restricted", "terseLabel": "Investment securities held in trust account" } } }, "localname": "TradingSecuritiesRestricted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "US Treasury Bill Securities [Member]" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r383", "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued for interest and penalties", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r158", "r159", "r161", "r162", "r166", "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "Variable Interest Entities" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntities" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesAdditionalInformationDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityMeasureOfActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Variable Interest Entity, Measure of Activity [Abstract]" } } }, "localname": "VariableInterestEntityMeasureOfActivityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r422", "r423", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary [Member]" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVieAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]", "verboseLabel": "Warrants, each whole warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per share [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CoverPage", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liabilities", "verboseLabel": "Warrants outstanding to purchase" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Fair value measurements inputs" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsInputsDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r415": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r481": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403832&loc=d3e34039-112682" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r502": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=123726495&loc=d3e600178-122990" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737436-115832" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r622": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r623": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r624": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r625": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r626": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r627": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r628": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r629": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r631": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r632": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r633": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r634": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r635": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r636": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r637": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r638": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r639": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r641": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r642": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r643": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r644": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r645": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r646": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" } }, "version": "2.1" }